Suppr超能文献

免疫球蛋白中的抗体多样性:新型免疫治疗药物的治疗机会。

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs.

机构信息

Institute of Pharmacology, University of Bern, Bern, Switzerland.

Sorbonne Université, Inserm, Assistance Publique Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Paris, France.

出版信息

Front Immunol. 2023 Mar 28;14:1166821. doi: 10.3389/fimmu.2023.1166821. eCollection 2023.

Abstract

Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represent the IgG repertoire of the donor population and will likely remain the cornerstone of antibody replacement therapy in immunodeficiencies. However, novel evidence suggests that pooled IgA might promote orthobiotic microbial colonization in gut dysbiosis linked to mucosal IgA immunodeficiency. Plasma-derived polyclonal IgG and IgA exhibit immunoregulatory effects by a diversity of different mechanisms, which have inspired the development of novel drugs. Here we highlight recent insights into IgG and IgA repertoires and discuss potential implications for polyclonal immunoglobulin therapy and inspired drugs.

摘要

在阐明人类抗体库方面取得了重大进展。此外,还发现了抗体的非典型功能,这些功能超出了与抵御病原体相关的经典功能。多克隆免疫球蛋白制剂,如 IVIG 和 SCIG,代表供体人群的 IgG 库,并且可能仍然是免疫缺陷症中抗体替代治疗的基石。然而,新的证据表明,在与黏膜 IgA 免疫缺陷相关的肠道菌群失调中,汇集的 IgA 可能促进共生微生物定植。血浆衍生的多克隆 IgG 和 IgA 通过多种不同的机制发挥免疫调节作用,这激发了新型药物的开发。在这里,我们重点介绍 IgG 和 IgA 库的最新研究进展,并讨论其对多克隆免疫球蛋白治疗和受启发药物的潜在影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bdf3/10090664/e20d79990555/fimmu-14-1166821-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验